FierceBiotechOriginal article
{"a":[{"_":"Lilly’s triple-G drug hits 22.6% weight loss, but impact on reducing cardio risk is less clear","$":{"href":"/biotech/lillys-triple-g-drug-hits-226-weight-loss-cardio-risk-impact-disappoints","hreflang":"en"}}]}
Phase 3MixedretatrutideNeutral
AI Analysis
Summary
Eli Lilly's retatrutide achieved primary endpoints in phase 3 obesity trials with 22.6% weight loss, though results fell short of previous trials and failed to demonstrate cardiovascular risk reduction benefit.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Hit primary endpoints in pair of phase 3 obesity trials; peak weight loss of 22.6% fell short of previous trials; failed to prove cardiovascular risk reduction
Importance:7/10
Sentiment:
0.20
obesityweight losscardiovascular riskphase 3 trialretatrutide
Related Companies
Read the original article
Published by FierceBiotech on July 23, 2026 8:20 AM